Given that a majority of pre-B ALL blasts express TRAIL-R1 and/or TRAIL-R2 [36] and that pre-B leukemia-initiating cells are sensitive to TRAIL-mediated apoptosis [37], our findings are of particular clinical interest to prevent ALL-relapse following HSCT. The gene discussed is TNFRSF10B; the disease is leukemia.